The Effect of Metformin on the Incidence of Type 2 Diabetes Mellitus and Cardiovascular Disease Risk Factors in Overweight and Obese Subjects – The Carmos Study

Andreadis, E.; Katsanou, Panagiota; Georgiopoulos, D.; Tsourous, G I; Yfanti, G.; Gouveri, Evanthia; Diamantopoulos, E J

doi:10.1055/s-0028-1087177

Cited by 27 publications

(47 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another type 2 model, db/db mice, rapamycin treatment improved diabetic renal hypertrophy [99]. Metformin has also been used successfully in the prevention of type 2 diabetes in patients with metabolic syndrome [100].…”

Section: Metabolic Syndromementioning

confidence: 99%

Aging and cancer: can mTOR inhibitors kill two birds with one drug?

Sharp¹,

Richardson

2011

Targ Oncol

View full text Add to dashboard Cite

The main risk factor for a number of diseases, including cancer, is aging. By delaying the effects of aging, many years of research indicate that diseases associated with aging are reduced by prolongevity interventions such as reductions in caloric intake and mice genetically deficient for growth factors. Although studies of dietary and growth factor restriction have been highly informative regarding the aging process, they are both unrealistic for human application. Recent preclinical results with a pharmacological prolongevity agent (rapamycin) provide a proof-of-concept that such an approach is feasible in human populations. Exactly how rapamycin works to extend lifespan is under increasingly intense investigation. In addition, these studies underscore the critical role that the intracellular target of rapamycin (TOR) plays in one of the deepest mysteries of life, aging. How age-associated diseases interface with TOR and its signaling systems, and the tremendous opportunities for discovery of new drugs that target both aging and its associated diseases is one of the most exciting areas of research currently being conducted in this new era of aging research.

show abstract

Section: Metabolic Syndromementioning

confidence: 99%

Aging and cancer: can mTOR inhibitors kill two birds with one drug?

Sharp¹,

Richardson

2011

Targ Oncol

View full text Add to dashboard Cite

show abstract

“…20). Metabolic syndrome Z-scores and ATP III criteria were calculated to describe the efficacy of each treatment on metabolic syndrome severity and total number of risk factors (18). Sex specific Z-scores were calculated as: male Z-score ¼ ((40ÀHDL)/10.7) þ ((TAGÀ 150/88.5)) þ ((FPGÀ100)/11.9) þ ((WCÀ102)/14.3) þ ((MAPÀ 100)/8.8), and female Z-score ¼ ((50ÀHDL)/11.0) þ ((TAGÀ150/ 88.5)) þ ((FPGÀ100)/11.9) þ ((WCÀ88)/13.6) þ ((MAPÀ100)/ 8.8).…”

Section: Biochemical Analysesmentioning

confidence: 99%

Metformin Modifies the Exercise Training Effects on Risk Factors for Cardiovascular Disease in Impaired Glucose Tolerant Adults

Malin¹,

Nightingale²,

Choi³

et al. 2012

Obesity

View full text Add to dashboard Cite

Impaired glucose tolerant (IGT) adults are at elevated risk for cardiovascular disease (CVD). Exercise or metformin reduce CVD risk, but the efficacy of combining treatments is unclear. To determine the effects of exercise training plus metformin, compared to each treatment alone, on CVD risk factors in IGT adults. Subjects were assigned to: placebo (P), metformin (M), exercise plus placebo (EP), or exercise plus metformin (EM) (8/group). In a double-blind design, P or 2000mg/d of M were administered for 12 weeks and half performed aerobic and resistance training 3 days/week for approximately 60 minutes/day at 70% pre-training heart rate peak. Outcomes included: adiposity, blood pressure (BP), lipids and high sensitivity C-reactive protein (hs-CRP). Z-scores were calculated to determine metabolic syndrome severity. M and EM, but not EP, decreased body weight compared to P (p <0.05). M and EP lowered systolic BP by 6% (p < 0.05), diastolic BP by 6% (p < 0.05), and hs-CRP by 20% (M: trend p = 0.06; EP: p < 0.05) compared to P. Treatments raised HDL-cholesterol (p < 0.05; EM: trend p = 0.06) compared to P and lowered triacyglycerol (p < 0.05) and metabolic syndrome Z-score compared to baseline (EP; trend p = 0.07 and EM or M; p < 0.05). Although exercise and/or metformin improve some CVD risk factors, only training or metformin alone lowered hs-CRP and BP. Thus, metformin may attenuate the effects of training on some CVD risk factors and metabolic syndrome severity in IGT adults.

show abstract

“…Cardiac pulsatility and aortic compliance may result in aortic annulus changes [3]. However, the dynamic changes of aortic annulus during the cardiac cycle have not been clarified in patients with aortic stenosis (AS) [4][5][6]. Knowledge of the dynamic characteristics of aortic annulus in this population may improve our understanding of aortic annulus and help accurately size aortic annulus.…”

mentioning

confidence: 98%

“…Several studies have shown that a reduction in endothelial function [2] may represent the link between IR and decline in cardiovascular performance. Treatment with metformin has been reported to prevent the above-mentioned cardiac abnormalities [3] and the evolution of IR diabetes [4]. However, metformin has also been shown to slightly but significantly reduce oxygen consumption in a population of healthy individuals [5].…”

mentioning

confidence: 99%

Cardiopulmonary and endothelial effects of metformin treatment in an insulin resistant population

Cadeddu

Deidda

Cadeddu

et al. 2012

International Journal of Cardiology

View full text Add to dashboard Cite

The Effect of Metformin on the Incidence of Type 2 Diabetes Mellitus and Cardiovascular Disease Risk Factors in Overweight and Obese Subjects – The Carmos Study

Abstract: Metformin reduces the occurrence of T (2)DM in overweight and obese non-diabetic adults and decreases the rate of MetS by improving the CVD risk factor profile.

Cited by 27 publications

References 20 publications

Aging and cancer: can mTOR inhibitors kill two birds with one drug?

Aging and cancer: can mTOR inhibitors kill two birds with one drug?

Metformin Modifies the Exercise Training Effects on Risk Factors for Cardiovascular Disease in Impaired Glucose Tolerant Adults

Cardiopulmonary and endothelial effects of metformin treatment in an insulin resistant population

Contact Info

Product

Resources

About